<VariationArchive VariationID="38192" VariationName="NM_000059.4(BRCA2):c.8904del (p.Val2969fs)" VariationType="Deletion" Accession="VCV000038192" Version="57" RecordType="classified" NumberOfSubmissions="27" NumberOfSubmitters="27" DateLastUpdated="2024-07-29" DateCreated="2014-04-01" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="46748" VariationID="38192">
      <GeneList>
        <Gene Symbol="BRCA2" FullName="BRCA2 DNA repair associated" GeneID="675" HGNC_ID="HGNC:1101" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32315508" stop="32400268" display_start="32315508" display_stop="32400268" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32889616" stop="32973808" display_start="32889616" display_stop="32973808" Strand="+" />
          </Location>
          <OMIM>600185</OMIM>
          <Haploinsufficiency last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2022</Property>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
        </Gene>
      </GeneList>
      <Name>NM_000059.4(BRCA2):c.8904del (p.Val2969fs)</Name>
      <CanonicalSPDI>NC_000013.11:32379464:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>13q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32379465" stop="32379465" display_start="32379465" display_stop="32379465" variantLength="1" positionVCF="32379464" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32953602" stop="32953602" display_start="32953602" display_stop="32953602" variantLength="1" positionVCF="32953601" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>9132delC</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.32953603del" Assembly="GRCh37">
            <Expression>NC_000013.10:g.32953603del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.11" sequenceAccession="NC_000013" sequenceVersion="11" change="g.32379466del" Assembly="GRCh38">
            <Expression>NC_000013.11:g.32379466del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012772.3" sequenceAccession="NG_012772" sequenceVersion="3" change="g.68987del">
            <Expression>NG_012772.3:g.68987del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.4" sequenceAccession="NM_000059" sequenceVersion="4" change="c.8904del" MANESelect="true">
            <Expression>NM_000059.4:c.8904del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000050.3" sequenceAccession="NP_000050" sequenceVersion="3" change="p.Val2969fs">
            <Expression>NP_000050.3:p.Val2969fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_293" sequenceAccession="LRG_293">
            <Expression>LRG_293:g.68987del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.3" sequenceAccession="NM_000059" sequenceVersion="3" change="c.8904delC">
            <Expression>NM_000059.3:c.8904delC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="U43746.1" sequenceAccession="U43746" sequenceVersion="1" change="n.9132delC">
            <Expression>U43746.1:n.9132delC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="9132&amp;base_change=del C" DB="Breast Cancer Information Core (BIC) (BRCA2)" />
        <XRef ID="CA025865" DB="ClinGen" />
        <XRef Type="rs" ID="80359730" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Breast-ovarian cancer, familial, susceptibility to, 2" Accession="RCV000031775" Version="19">
        <ClassifiedConditionList TraitSetID="2560">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2016-04-22" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Hereditary breast ovarian cancer syndrome" Accession="RCV000045650" Version="31">
        <ClassifiedConditionList TraitSetID="7920">
          <ClassifiedCondition DB="MedGen" ID="C0677776">Hereditary breast ovarian cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-16" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000131370" Version="22">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-12-14" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND not provided" Accession="RCV000216861" Version="36">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-09-29" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Breast and/or ovarian cancer" Accession="RCV000735615" Version="11">
        <ClassifiedConditionList TraitSetID="20192">
          <ClassifiedCondition DB="MedGen" ID="CN221562">Breast and/or ovarian cancer</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-02-11" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Malignant tumor of breast" Accession="RCV001353455" Version="10">
        <ClassifiedConditionList TraitSetID="25616">
          <ClassifiedCondition DB="MedGen" ID="C0006142">Malignant tumor of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND multiple conditions" Accession="RCV002482935" Version="8">
        <ClassifiedConditionList TraitSetID="19216">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1838457">Fanconi anemia complementation group D1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2751641">Glioma susceptibility 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0376358">Malignant tumor of prostate</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0025149">Medulloblastoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3150546">Pancreatic cancer, susceptibility to, 2</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN033288">Wilms tumor 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.8904del (p.Val2969fs) AND Familial cancer of breast" Accession="RCV002272034" Version="11">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-31" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-04-22" NumberOfSubmissions="27" NumberOfSubmitters="27" DateCreated="2014-04-01" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10359546</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12750261</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12920083</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12960223</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15026808</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15635067</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16234499</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18445692</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18563556</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20104584</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20807450</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20815029</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21952622</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22711857</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23035815</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23199084</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23569310</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23569316</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25186627</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26187060</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26724258</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27225637</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28284943</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28831036</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29446198</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32853339</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32885271</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33471991</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33720054</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9667259</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2560" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25616" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="34847" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of breast</ElementValue>
                <XRef ID="254837009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant breast neoplasm</ElementValue>
                <XRef ID="C9335" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer breast</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="pmc">2936467</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2018">
                <ID Source="PubMed">29939840</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">30452337</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2018">
                <URL>https://www.nice.org.uk/guidance/dg34</URL>
                <CitationText>Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="C0006142" DB="MedGen" />
              <XRef ID="MONDO:0007254" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="20192" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="32337" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
                <XRef ID="UWMG_7622958" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <XRef ID="CN221562" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="19216" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="4506" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Wilms tumor, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Wilms tumor 1</ElementValue>
                <XRef ID="MONDO:0008679" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">WT1</ElementValue>
                <XRef Type="MIM" ID="194070" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15124" />
                <XRef ID="15124" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Wilms Tumor (Nephroblastoma), 2023</CitationText>
              </Citation>
              <XRef ID="654" DB="Orphanet" />
              <XRef ID="CN033288" DB="MedGen" />
              <XRef ID="MONDO:0008679" DB="MONDO" />
              <XRef Type="MIM" ID="194070" DB="OMIM" />
            </Trait>
            <Trait ID="6902" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Glioma susceptibility 3</ElementValue>
                <XRef ID="Glioma+susceptibility+3/8470" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013093" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glioblastoma 3</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GLM3</ElementValue>
                <XRef Type="MIM" ID="613029" DB="OMIM" />
              </Symbol>
              <XRef ID="182067" DB="Orphanet" />
              <XRef ID="360" DB="Orphanet" />
              <XRef ID="C2751641" DB="MedGen" />
              <XRef ID="MONDO:0013093" DB="MONDO" />
              <XRef Type="MIM" ID="613029" DB="OMIM" />
            </Trait>
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
            <Trait ID="1276" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group D1</ElementValue>
                <XRef ID="MONDO:0011584" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FAD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FANCD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17449" />
                <XRef ID="17449" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="Suggested Reading">
                <ID Source="PubMed">14559878</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="319462" DB="Orphanet" />
              <XRef ID="C1838457" DB="MedGen" />
              <XRef ID="MONDO:0011584" DB="MONDO" />
              <XRef Type="MIM" ID="605724" DB="OMIM" />
            </Trait>
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
            <Trait ID="2738" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Medulloblastoma, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Medulloblastoma</ElementValue>
                <XRef ID="Medulloblastoma/4552" DB="Genetic Alliance" />
                <XRef ID="HP:0002885" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007959" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEDULLOBLASTOMA PREDISPOSITION SYNDROME</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
                <XRef Type="Allelic variant" ID="612250.0002" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MDB</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7005" />
                <XRef ID="7005" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers, 2023</CitationText>
              </Citation>
              <XRef ID="616" DB="Orphanet" />
              <XRef ID="C0025149" DB="MedGen" />
              <XRef ID="D008527" DB="MeSH" />
              <XRef ID="MONDO:0007959" DB="MONDO" />
              <XRef Type="MIM" ID="155255" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002885" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="6821" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pancreatic cancer 2</ElementValue>
                <XRef ID="Pancreatic+cancer+2/9069" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pancreatic cancer, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0013235" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PNCA2</ElementValue>
                <XRef Type="MIM" ID="613347" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="1333" DB="Orphanet" />
              <XRef ID="C3150546" DB="MedGen" />
              <XRef ID="MONDO:0013235" DB="MONDO" />
              <XRef Type="MIM" ID="613347" DB="OMIM" />
            </Trait>
            <Trait ID="5807" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Prostate cancer</ElementValue>
                <XRef ID="HP:0012125" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008315" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of prostate</ElementValue>
                <XRef ID="Prostate+cancer/9175" DB="Genetic Alliance" />
                <XRef ID="399068003" DB="SNOMED CT" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2014">
                <ID Source="PubMed">24071797</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="AUA, 2018">
                <ID Source="PubMed">23659877</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Prostate cancer genetics">
                <ID Source="PubMed">26389227</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2021">
                <ID Source="PubMed">33497248</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">31829902</ID>
              </Citation>
              <Citation Type="general" Abbrev="HKUA/HKSU-O, 2022">
                <ID Source="PubMed">35924163</ID>
                <ID Source="pmc">9339641</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng131</URL>
                <CitationText>UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021</CitationText>
              </Citation>
              <XRef ID="1331" DB="Orphanet" />
              <XRef ID="C0376358" DB="MedGen" />
              <XRef ID="MONDO:0008315" DB="MONDO" />
              <XRef Type="primary" ID="HP:0012125" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7920" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16761" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer</ElementValue>
                <XRef ID="UWMG_4506306" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary breast ovarian cancer syndrome</ElementValue>
                <XRef ID="MONDO:0003582" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast and ovarian cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome (HBOC)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and/or ovarian cancer syndrome</ElementValue>
                <XRef ID="145" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome</ElementValue>
                <XRef ID="D061325" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HBOC</ElementValue>
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15010" />
                <XRef ID="15010" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512699" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502103" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595973" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508566" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508956" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508948" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551441" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520887" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521499" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561859" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503369" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523320" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C0677776" DB="MedGen" />
              <XRef ID="D061325" DB="MeSH" />
              <XRef ID="MONDO:0003582" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1688959" SubmissionDate="2018-07-18" DateLastUpdated="2018-12-24" DateCreated="2018-12-24">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|MedGen:CN221562" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000863753" DateUpdated="2018-12-24" DateCreated="2018-12-24" Type="SCV" Version="1" SubmitterName="Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research" OrgID="500086" OrganizationCategory="laboratory" OrgAbbreviation="WDFlab" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-09-11">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN221562" Type="CUI" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB4310295</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1795607" SubmissionDate="2021-02-09" DateLastUpdated="2021-02-12" DateCreated="2019-05-31">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000918986" DateUpdated="2021-02-12" DateCreated="2019-05-31" Type="SCV" Version="2" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18563556</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12750261</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15635067</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16234499</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12920083</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10359546</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18445692</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26187060</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Comment>Variant summary: BRCA2 c.8904delC (p.Val2969CysfsX7) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 249760 control chromosomes. c.8904delC has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (example, Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Multiple clinical diagnostic laboratories, one consortium (CIMBA) and one expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9051234</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="264380" SubmissionDate="2014-03-28" DateLastUpdated="2014-04-01" DateCreated="2014-04-01">
        <ClinVarSubmissionID localKey="U43746.1:n.9132delC|MedGen:C2675520" />
        <ClinVarAccession Accession="SCV000147482" DateUpdated="2014-04-01" DateCreated="2014-04-01" Type="SCV" Version="1" SubmitterName="Breast Cancer Information Core (BIC) (BRCA2)" OrgID="504197" OrganizationCategory="locus-specific database (LSDB)" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-05-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="14" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Western European</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>English</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="14" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European, Native American</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European, Portuguese</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>U43746.1:exon 22</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>9132delC</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="80359730" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">U43746.1:n.9132delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1570740" SubmissionDate="2018-01-29" DateLastUpdated="2018-09-13" DateCreated="2018-09-13">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000805789" DateUpdated="2018-09-13" DateCreated="2018-09-13" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-01-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3589995</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1148679" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2017-08-27">
        <ClinVarSubmissionID localKey="chr13:32953600-32953602:30e641edc63ecdd5d97378f703e20eb1-BREAST" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000592235" DateUpdated="2021-04-13" DateCreated="2017-08-27" Type="SCV" Version="2" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2, p.Val2969CysfsX7 variant was identified in 4 of 5018 proband chromosomes (frequency: 0.001) from individuals or families with breast, ovarian and prostate cancer (De Leeneer 2010, Evans 2003, Frank 1998, Kote-Jarai 2011). The variant was also identified in dbSNP (ID: rs80359730) â€šÃ„ÃºWith pathogenic alleleâ€šÃ„Ã¹, HGMD, the ClinVar database (classified as a pathogenic variant by the Sharing Clinical Reports Project, derived from Myriad reports; BIC and Ambry Genetics), GeneInsight VariantWire database (2X, classified as â€šÃ„Ãºpathogenicâ€šÃ„Ã¹ by a clinical laboratory) and the BIC database (37X with clinical importance).The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. The p.Val2969CysfsX7 deletion variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 2969 and leads to a premature stop codon 7 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="A" referenceAllele="AC" start="32953601" stop="32953602" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007254" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3374871" SubmissionDate="2021-05-26" DateLastUpdated="2021-06-15" DateCreated="2021-06-15">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001714438" DateUpdated="2021-06-15" DateCreated="2021-06-15" Type="SCV" Version="1" SubmitterName="Mayo Clinic Laboratories, Mayo Clinic" OrgID="500068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-02-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">18445692</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23569310</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26724258</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23035815</ID>
          </Citation>
          <Comment>PVS1, PS4_Mod, PM2, PP5</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000059.3:exon 22</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Val2969Cysfs*7</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9741791</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5450144" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904del|OMIM:114480;155255;176807;194070;605724;612555;613029;613347" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002800844" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="155255" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="176807" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="194070" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605724" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613029" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613347" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2284918" SubmissionDate="2023-01-06" DateLastUpdated="2023-06-10" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2233281|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001160334" DateUpdated="2023-06-10" DateCreated="2020-02-10" Type="SCV" Version="4" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.8904delC; p.Val2969CysfsTer7 variant (rs80359730), also known as 9132delC for traditional nomenclature, is reported in the literature in individuals with breast, ovarian, or prostate cancer (Claes 2004, Frank 1998, Kote-Jarai 2011). This variant is classified as pathogenic by an expert review panel in ClinVar (Variation ID: 38192). It is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Claes K et al. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer. 2004 Mar 22;90(6):1244-51. Frank TS et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul;16(7):2417-25. Kote-Jarai Z et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011 Oct 11;105(8):1230-4.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/ythvkvge/arup_molecular_germline_variant_investigation_process_2021.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953603del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>Aug 2019 ARUP</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7117916" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="e0939cea5117e240e7572197c123abb5c5a8a42050548cf1f69458c1305e87ac|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003815003" DateUpdated="2024-02-04" DateCreated="2023-03-04" Type="SCV" Version="2" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12922107</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="556589" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2016-07-08">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkRezt7a_ic-S_4uzQjOR4wo|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000292151" DateUpdated="2024-02-14" DateCreated="2016-07-08" Type="SCV" Version="5" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10359546</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12750261</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12920083</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12960223</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15635067</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16234499</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18445692</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18563556</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20807450</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20815029</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22711857</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23035815</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23569316</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25186627</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26724258</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28831036</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33471991</ID>
          </Citation>
          <Comment>This variant deletes 1 nucleotide in exon 22 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least 11 individuals affected with breast or ovarian cancer (PMID: 9667259, 10359546, 12750261, 15635067, 18445692, 18563556, 20807450, 22711857, 25186627, 28831036) and in a breast cancer case-control meta-analysis in 6/60463 cases and 1/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_001079). This variant also has been reported in several dozens of individuals and families suspected of being affected with hereditary breast and ovarian cancer (PMID: 12920083, 12960223, 15026808, 16234499, 20815029, 29446198) and in individuals affected with prostate cancer (PMID: 18445692, 21952622, 23035815, 23569316, 26724258). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ColorClinVarSubmissionJune2021_SUB9834248</SubmissionName>
          <SubmissionName>SUB10906337</SubmissionName>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="121593" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2013-07-03">
        <ClinVarSubmissionID localKey="606043|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000073663" DateUpdated="2024-02-20" DateCreated="2013-07-03" Type="SCV" Version="13" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20104584</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23035815</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28284943</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val2969Cysfs*7) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with prostate cancer and a personal and/or family history of breast cancer (PMID: 9667259, 15026808, 21952622, 23035815, 28284943). This variant is also known as 9132delC. ClinVar contains an entry for this variant (Variation ID: 38192). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953602del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9032835" SubmissionDate="2024-04-16" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="1539849|MONDO:0012933" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004846089" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="All of Us Research Program, National Institutes of Health" OrgID="509529" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10359546</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12750261</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12920083</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12960223</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15635067</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16234499</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18445692</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18563556</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20807450</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20815029</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22711857</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23035815</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23569316</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25186627</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26724258</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28831036</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33471991</ID>
          </Citation>
          <Comment>This variant deletes 1 nucleotide in exon 22 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least 11 individuals affected with breast or ovarian cancer (PMID: 9667259, 10359546, 12750261, 15635067, 18445692, 18563556, 20807450, 22711857, 25186627, 28831036) and in a breast cancer case-control meta-analysis in 6/60463 cases and 1/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_001079). This variant also has been reported in several dozens of individuals and families suspected of being affected with hereditary breast and ovarian cancer (PMID: 12920083, 12960223, 15026808, 16234499, 20815029, 29446198) and in individuals affected with prostate cancer (PMID: 18445692, 21952622, 23035815, 23569316, 26724258). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>108544</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953603del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012933" />
          </Trait>
        </TraitSet>
        <Comment>This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB14382316</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7863318" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000059.4:c.8904del|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004213680" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="89998" SubmissionDate="2013-08-08" DateLastUpdated="2014-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="SCRP_var_827" title="NM_000059.3:c.8904delC AND Breast-ovarian cancer, familial 2" />
        <ClinVarAccession Accession="SCV000054383" DateUpdated="2014-09-27" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="Sharing Clinical Reports Project (SCRP)" OrgID="500037" OrganizationCategory="consortium" OrgAbbreviation="SCRP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2012-12-03">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <NumberTested>14</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles">14</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="nucleotide change">9132delC</Name>
            <Name Type="nucleotide change">9132DELC</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="502997" SubmissionDate="2016-04-21" DateLastUpdated="2014-09-27" DateCreated="2014-09-27">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000267823" DateUpdated="2014-09-27" DateCreated="2014-09-27" Type="SCV" Version="1" SubmitterName="Michigan Medical Genetics Laboratories, University of Michigan" OrgID="308659" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-04-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Tissue>Blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80359730" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="537195" SubmissionDate="2016-06-09" DateLastUpdated="2016-06-24" DateCreated="2016-06-24">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000282464" DateUpdated="2016-06-24" DateCreated="2016-06-24" Type="SCV" Version="1" SubmitterName="Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)" OrgID="504863" OrganizationCategory="consortium" OrgAbbreviation="ENIGMA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-04-22">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant allele predicted to encode a truncated non-functional protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ENIGMA BRCA1/2 Classification Criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/c2ffjci6/enigma_rules_2015-03-26.pdf</URL>
            <CitationText>ENIGMA BRCA1/2 Classification Criteria (2015)</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>9132delC</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyDescription>ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is a consortium focused on determining the clinical significance of variants in BRCA1, BRCA2 and other known/suspected breast cancer genes. http://enigmaconsortium.org/</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>ENIGMA_2015-08-17</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1139914" SubmissionDate="2017-08-04" DateLastUpdated="2017-04-16" DateCreated="2017-04-16">
        <ClinVarSubmissionID localKey="460246|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000586987" DateUpdated="2017-04-16" DateCreated="2017-04-16" Type="SCV" Version="1" SubmitterName="Cancer Genetics and Genomics Laboratory, British Columbia Cancer Agency" OrgID="506183" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-04-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NC_000013.10:g.32953603delC</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>CCG20170515</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1140902" SubmissionDate="2017-08-04" DateLastUpdated="2017-04-16" DateCreated="2017-04-16">
        <ClinVarSubmissionID localKey="291070|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000587975" DateUpdated="2017-04-16" DateCreated="2017-04-16" Type="SCV" Version="1" SubmitterName="Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto" OrgID="506247" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-01-31">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000059.3:c.8904delC</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953603delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>RMGL-WCRI-05152017</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1141050" SubmissionDate="2017-08-04" DateLastUpdated="2017-04-16" DateCreated="2017-04-16">
        <ClinVarSubmissionID localKey="724129|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000588123" DateUpdated="2017-04-16" DateCreated="2017-04-16" Type="SCV" Version="1" SubmitterName="Department of Pathology and Molecular Medicine, Queen's University" OrgID="506188" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-04-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000059.3:c.8904delC</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953603delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>QUEENSU-06202017</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="623156" SubmissionDate="2018-04-30" DateLastUpdated="2019-05-06" DateCreated="2016-01-31">
        <ClinVarSubmissionID localKey="300142|MedGen:CN221562" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000324883" DateUpdated="2019-05-06" DateCreated="2016-01-31" Type="SCV" Version="2" SubmitterName="CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario" OrgID="1050" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-02-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN221562" Type="CUI" />
          </Trait>
        </TraitSet>
        <StudyName>Canadian Open Genetics Repository</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB3960680</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1169499" SubmissionDate="2020-06-03" DateLastUpdated="2020-07-03" DateCreated="2017-08-27">
        <ClinVarSubmissionID localKey="70845021|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000605797" DateUpdated="2020-07-03" DateCreated="2017-08-27" Type="SCV" Version="3" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-04-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Comment>The p.Val2969CysfsX7 variant in BRCA2 has been reported at least 40 individuals with BRCA2-associated cancers (Claes 2004, Kote-Jarai 2011, Frank 1998, Breast Cancer Information Core (BIC) database), and was absent from large population studies. This variant is predicted to cause a frameshift, which alters the proteinâ€™s amino acid sequence beginning at position 2969 and leads to a premature termination codon 7 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the BRCA2 gene is an established disease mechanism in hereditary breast and ovarian cancer (HBOC). In addition, this variant was classified as Pathogenic on April 22, 2016 by the ClinGen-approved ENIGMA expert panel (ClinVar SCV000282464.1). In summary, the p.Val2969CysfsX7 variant meets criteria to be classified as pathogenic for HBOC in an autosomal dominant manner based upon the predicted impact to the protein. ACMG/AMP Criteria applied: PVS1, PS4, PM2.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="3" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32953603delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7546315</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4951366" SubmissionDate="2022-04-25" DateLastUpdated="2022-06-24" DateCreated="2022-06-24">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904delC|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002531985" DateUpdated="2022-06-24" DateCreated="2022-06-24" Type="SCV" Version="1" SubmitterName="Sema4, Sema4" OrgID="500057" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32885271</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32853339</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Sema4 Curation Guidelines</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/cy0kpury/sema4_variant_curation_guidelines-clinvar_april_2022.docx</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <Comment>The BRCA2 c.8904delC (p.V2969CfsX7) variant has been reported in heterozygosity in several individuals with breast cancer and prostate cancer (PMID: 9667259, 21952622, 32885271, 15026808, 32853339) besides various other publications in literature citing additional patients. This variant causes a frameshift at amino acid 2969 that results in premature termination 7 amino acids downstream. At this location, this is predicted to cause nonsense-mediated decay and result in an absent protein (loss of function). Loss of function variants in BRCA2 are known to be pathogenic (PMID: 29446198). This variant is not reported in the population database Genome Aggregation Database (http://gnomad.broadinstitute.org, PMID: 32461654). This variant has been reported in ClinVar (Variation ID: 38192). Based on the current evidence available, this variant is interpreted as pathogenic.</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB11360768</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="627093" SubmissionDate="2016-10-28" DateLastUpdated="2022-12-11" DateCreated="2016-11-05">
        <ClinVarSubmissionID localKey="NM_000059.3:c.8904del|OMIM:612555" submittedAssembly="hg18" />
        <ClinVarAccession Accession="SCV000327985" DateUpdated="2022-12-11" DateCreated="2016-11-05" Type="SCV" Version="4" SubmitterName="Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge" OrgID="505954" OrganizationCategory="consortium" OrgAbbreviation="CIMBA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CIMBA Mutation Classification guidelines May 2016</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/nhgqiuyb/cimba_mutation_classification_guidelines_may16.pdf</URL>
            <CitationText>CIMBA_Mutation_Classification_guidelines_May16.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="66" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>CIMBA_20161005</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5002857" SubmissionDate="2022-12-11" DateLastUpdated="2022-12-17" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="sa_pathology/molecular_pathology_fmc/vc23174" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002556903" DateUpdated="2022-12-17" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Genetics and Molecular Pathology, SA Pathology" OrgID="506043" OrganizationCategory="laboratory" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.8904delC variant is classified as Pathogenic (PVS1, PM2) This BRCA2 c.8904delC variant is located in exon 22/27 and is predicted to cause a shift in the reading frame at codon 2969. The variant is rare in population databases and has been reported as Pathogenic by other diagnostic laboratories (ClinVar Variation ID: 38192).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_8174</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_33</SubmissionName>
          <SubmissionName>submission_36</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="515746" SubmissionDate="2022-06-08" DateLastUpdated="2023-03-04" DateCreated="2016-05-29">
        <ClinVarSubmissionID localKey="GDXSV:229698" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000278884" DateUpdated="2023-03-04" DateCreated="2016-05-29" Type="SCV" Version="14" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Frank 1998, Lalloo 2003, Kote-Jarai 2011, Willems-Jones 2012, Castro 2013, Cheng 2016); Not observed at significant frequency in large population cohorts (gnomAD); Also known as 9132delC; This variant is associated with the following publications: (PMID: 12672316, 15026808, 21952622, 9667259, 23199084, 23569316, 23035815, 15131399, 26724258, 27225637, 32338768, 33654310, 33087929, 30787465, 32885271, 32853339)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:8944</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_111_20220608054204</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_18_20210720144155</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_62_20211022152658</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1164525" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2016-10-09">
        <ClinVarSubmissionID localKey="S339|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000600830" DateUpdated="2024-01-06" DateCreated="2016-10-09" Type="SCV" Version="5" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">33720054</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26724258</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27225637</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21952622</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23035815</ID>
          </Citation>
          <Comment>This frameshift variant causes the premature termination of BRCA2 protein synthesis. In addition, it has been reported in individuals with breast/ovarian cancer or prostate cancer in the published literature (PMID: 15026808 (2004), 21952622 (2011), 23035815 (2012), 26724258 (2016)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB4481696</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="304861" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2014-08-06">
        <ClinVarSubmissionID localKey="a83838|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000186346" DateUpdated="2024-05-01" DateCreated="2014-08-06" Type="SCV" Version="8" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15026808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23199084</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26724258</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9667259</ID>
          </Citation>
          <Comment>The c.8904delC pathogenic mutation, located in coding exon 21 of the BRCA2 gene, results from a deletion of one nucleotide at position 8904, causing a translational frameshift with a predicted alternate stop codon (p.V2969Cfs*7). This mutation was previously identified in a patient with early-onset breast cancer who had a family history of breast cancer (Frank TS et al. J. Clin. Oncol. 1998 Jul;16:2417-25), as well as in individuals diagnosed with prostate cancer (Kote-Jarai Z et al. Br. J. Cancer. 2011 Oct;105:1230-4; Willems-Jones A et al. BJU Int. 2012 Dec;110(11 Pt C):E1181-6; Cheng HH et al. Eur. Urol. 2016 Jun;69:992-5). This alteration has also been seen as a recurrent mutation in breast and/or ovarian cancer families of Belgian descent (Claes K et al. Br. J. Cancer. 2004 Mar;90:1244-51; Janaviius R. EPMA J. 2010 Sep;1:397-412). Of note, this alteration is also designated as 9132delC in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.8904delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9032835" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012933" MappingRef="MONDO">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="623156" TraitType="Disease" MappingType="Name" MappingValue="Breast and/or ovarian cancer" MappingRef="Preferred">
        <MedGen CUI="CN221562" Name="Breast and/or ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3374871" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="627093" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="605724" MappingRef="OMIM">
        <MedGen CUI="C1838457" Name="Fanconi anemia complementation group D1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="537195" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="89998" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="304861" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="515746" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7117916" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1688959" TraitType="Disease" MappingType="Name" MappingValue="Breast and/or ovarian cancer" MappingRef="Preferred">
        <MedGen CUI="CN221562" Name="Breast and/or ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1148679" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007254" MappingRef="MONDO">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1141050" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="502997" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1164525" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2284918" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="556589" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1140902" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1570740" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1795607" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="155255" MappingRef="OMIM">
        <MedGen CUI="C0025149" Name="Medulloblastoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1169499" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="176807" MappingRef="OMIM">
        <MedGen CUI="C2931456" Name="Familial prostate carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5002857" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="613347" MappingRef="OMIM">
        <MedGen CUI="C3150546" Name="Pancreatic cancer, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="121593" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7863318" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="264380" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1139914" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4951366" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="194070" MappingRef="OMIM">
        <MedGen CUI="CN033288" Name="Wilms tumor 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="613029" MappingRef="OMIM">
        <MedGen CUI="C2751641" Name="Glioma susceptibility 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5450144" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-11-13">SCV001853377</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

